Cytophage Technologies (TSXV:CYTO) EV-to-Revenue : (As of Jun. 02, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cytophage Technologies's enterprise value is C$25.91 Mil. Cytophage Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil. Therefore, Cytophage Technologies's EV-to-Revenue for today is .

The historical rank and industry rank for Cytophage Technologies's EV-to-Revenue or its related term are showing as below:

TSXV:CYTO's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.1
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-02), Cytophage Technologies's stock price is C$0.49. Cytophage Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00. Therefore, Cytophage Technologies's PS Ratio for today is .

Cytophage Technologies EV-to-Revenue Historical Data

The historical data trend for Cytophage Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies EV-to-Revenue Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-Revenue

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
EV-to-Revenue	-	-	-	-	-

Competitive Comparison of Cytophage Technologies's EV-to-Revenue

For the Biotechnology subindustry, Cytophage Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's EV-to-Revenue falls into.

Cytophage Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cytophage Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	25.905	/	0
	=

Cytophage Technologies's current Enterprise Value is C$25.91 Mil.
Cytophage Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Cytophage Technologies (TSXV:CYTO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cytophage Technologies's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.49	/	0
	=

Cytophage Technologies's share price for today is C$0.49.
Cytophage Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

Cytophage Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.